Testing an AI model that predicts when prostate cancer stops responding to hormone therapy
Tests an AI model predicting time to castration resistance in prostate cancer.
Plain-language title generated from the registry record
Registry title: Development and Prospective Validation of a Pathology-Based Artificial Intelligence Model for Predicting the Time to Castration Resistance of Prostate Cancer
Key facts
- Where
- Guangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with intermediate- to high-risk prostate cancer who had a prostate biopsy and received only hormone (endocrine) therapy. It tests an AI model that predicts the time to castration resistance.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Intermediate- to high-risk prostate cancer
- Earlier treatment
- Only endocrine (hormone) therapy for prostate cancer
Main reasons for not taking part
- Other tumors treated with systemic therapy
- Refusing to take part in this diagnostic test
- Incomplete clinical and pathological information
Read by machine on 12 November 2026.
Where in China
- Sun Yat Sen Memorial Hospital of Sun Yat sen UniversityGuangzhou, ChinaContact: Cuimei YaoNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Trial code
- NCT07376057
- Record updated
- 29 January 2026
- Original description
The goal of this predictive test is to prospectively test the performance of pre-developed artificial intelligence (AI) predictive model for predicting the time to castration resistance of prostate cancer. Investigators had developed this AI model based on deep learning algorithms in preliminary research, and it performed well in retrospective tests.Read full original descriptionShow less
Development and Prospective Validation of a Pathology-Based Artificial Intelligence Model for Predicting the Time to Castration Resistance of Prostate Cancer
The goal of this predictive test is to prospectively test the performance of pre-developed artificial intelligence (AI) predictive model for predicting the time to castration resistance of prostate cancer. Investigators had developed this AI model based on deep learning algorithms in preliminary research, and it performed well in retrospective tests.
Inclusion: Patients are diagnosed with intermediate- to high-risk prostate cancer; undergo prostate biopsy; Patients only received endocrine therapy for prostate cancer; Patients with complete clinical and pathological information; Patients agree to participate in this diagnostic test.
Exclusion: Patients with other tumors and undergo systemic therapy ; The patient refused to participate in this diagnostic test.